Related Experiment Video

Updated: May 5, 2026

DNA Fingerprinting of Mycobacterium leprae Strains Using Variable Number Tandem Repeat VNTR - Fragment Length Analysis FLA
09:39

DNA Fingerprinting of Mycobacterium leprae Strains Using Variable Number Tandem Repeat VNTR - Fragment Length Analysis FLA

Published on: July 15, 2011

26.6K

Role of toll-interacting protein gene polymorphisms in leprosy Mexican patients

Margarita Montoya-Buelna1, Mary Fafutis-Morris, Alvaro J Tovar-Cuevas

  • 1Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jal., Mexico ; Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jal., Mexico.

Biomed Research International
|December 3, 2013
PubMed
Abstract

Insights

Genetic factors influence leprosy susceptibility. A study found that the Toll-interacting protein (TOLLIP) gene variant rs3750920 C/C genotype may offer a protective effect against lepromatous leprosy in Mexican patients.

Area of Science:

  • Immunogenetics
  • Infectious Diseases
  • Human Genetics

Background:

  • Leprosy is a significant infectious disease affecting skin and nerves, with host genetic factors influencing susceptibility.
  • The Toll-interacting protein (TOLLIP) gene is crucial in the Toll-like receptor (TLR) pathway, regulating immune responses to pathogens.

Purpose of the Study:

  • To investigate the association between Toll-interacting protein (TOLLIP) gene variants and susceptibility to leprosy in a Mexican population.

Main Methods:

  • A case-control study was conducted on Mexican patients with lepromatous leprosy (LL) and healthy subjects (HS).
  • TOLLIP gene polymorphisms at rs5743854, rs3750920, rs5744015, and rs3750919 were analyzed using PCR with sequence-specific primers.

Main Results:

  • Genotype distributions adhered to Hardy Weinberg equilibrium, except for rs3750920.
  • No statistically significant differences in genotype or allele frequencies were observed between LL patients and controls (P > 0.05).
  • Linkage analysis showed a maximum pairwise D' coefficient of 0.44 (P = 0.01) for polymorphisms, excluding rs5743854; haplotype comparisons revealed no significant intergroup differences.

Conclusions:

  • A trend suggests that individuals with the rs3750920 C/C genotype may have a protective effect against developing lepromatous leprosy (LL).

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K
Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major08:17

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

1.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100